Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CellCoTec BV

www.cellcotec.com

Latest From CellCoTec BV

Progress In Cartilage Repair: The Holy Grail Of Knee OA

Researchers have been working for years to develop a reliable and cost-effective means of regenerating the hyaline cartilage found in the knee, with the aim of offering a minimally invasive treatment option for the millions of patients with painful knee osteoarthritis. Although this goal has been elusive so far, recent progress suggests the field may have turned a corner, and a large number of companies are now competing to win this quest, which many refer to as the “Holy Grail” of knee OA.

Medical Device

The Future of the Stem Cell Market

The stem cell market is beginning to show signs of significant revenue growth ahead, a development fueled by research in a variety of disease categories, some of which has already produced accepted therapies. In February, about three dozen firms gathered at the 5th Annual Stem Cell Summit, where participants showcased their technology in the hopes of securing financing.
BioPharmaceutical Regenerative Medicine

Cartilage Repair: What's the Right Combination?

START-UP counts some 40 commercial development efforts in cartilage repair and regeneration. Some are implanting synthetic scaffolds, and some are offering cell-based therapies used with or without scaffolds. It's a crowded and confusing category. So many companies are chasing a market that is still somewhat undefined and doesn't seem large enough to support them all. What's clear, however, is that almost 15 years after the introduction of Carticel, the first cell-based implant for cartilage repari, there is still an unsatisified market of patients aged 20-60 with knee pain due to cartilage damage or degeneration.
Medical Device Platform Technologies

Cartilage Repair: Bridging the Gap

With the era of regenerative medicine upon us, fueled in part by the Obama administration's lifting of the ban on government funding for stem cell research, advancements in biological approaches to orthopedic joint restoration are in the forefront. Most orthopedic surgeons believe that the future treatment of musculoskeletal problems no longer lies in replacing joints with metallic implants but in the development of curative therapies involving cells, growth factors, and other bioactive agents capable of regenerating bone, cartilage, and other joint structures. Although such products are still in the early stages of development, there has been a recent surge of interest in this area. Based on the wealth of new technologies presented at this year's American Academy of Orthopaedic Surgeons meeting held recently in Las Vegas, it is clear that stakeholders in this industry are in hot pursuit of this opportunity, which could one day be measured in the billions of dollars.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • CellCoTec BV
  • Senior Management
  • Ian Paling, Chmn. & CEO
    Jens Riesle, PhD, CSO & Exec. Dir.
  • Contact Info
  • CellCoTec BV
    Phone: (31) (0)30 229 7237
    Prof. Bronkhorstlaan 10D
    3723 MB Bilthov
    Bilthoven, 3723
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register